Torrent Pharmaceuticals has appointed Shanti Ekambaram as an Additional Independent Director on its Board of Directors. The appointment is effective from July 30, 2026, for a term of three consecutive years, subject to the approval of the company’s shareholders. This addition strengthens the board with a leader who brings 39 years of experience in financial services and corporate governance.

The Board approved the appointment based on the recommendation of the Nomination and Remuneration Committee. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Ekambaram is not related to any other director of the company and is not debarred from holding office by SEBI or any other authority.

Appointment Details

The key parameters of the new board appointment are summarized below:

Professional Background

Shanti Ekambaram, aged 63, is a Chartered Accountant and Cost Accountant with a distinguished career spanning nearly four decades. She spent 35 years at Kotak Mahindra Bank, playing a pivotal role in its transformation from a pre-IPO non-banking financial company into a leading universal bank. From 2022 to 2025, she served as Deputy Managing Director and Whole-time Director, overseeing Digital Banking, Treasury, Human Resources, Internal Audit, Vigilance, CSR/ESG, and Capital Market subsidiaries.

Her expertise extends to investment banking; she served as CEO of Kotak Mahindra Capital Company from 1997 to 2003. During this tenure, she led the Hughes Software IPO in 1999, which was India’s first book-building transaction, requiring intensive collaboration with SEBI and market participants to reform IPO mechanisms.

Current Board Memberships

Ekambaram currently serves on several prominent boards, reflecting her standing in both financial and industrial sectors:

• Kotak Mahindra Capital Company
• Kotak Securities
• Havells India Limited
• Indian Institute of Management, Bangalore

Her industry recognition includes being ranked No. 1 on the Candere Hurun India Women Leaders List 2025 and named Business Woman of the Year 2025 by The CEO Magazine. She has also been consistently featured in Fortune India’s '50 Most Powerful Women in Business' and Business Today’s 'Most Powerful Women in Indian Business' lists.

Torrent Pharmaceuticals Ltd has secured final listing and trading approval for 4,19,22,416 fully paid-up equity shares issued pursuant to its Scheme of Amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The new shares will begin trading on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) effective July 28, 2026, marking a key procedural milestone in the consolidation of the two pharmaceutical entities.

The approval follows the allotment of these shares to eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited based on the record date of Friday, July 17, 2026. Each share carries a face value of ₹ 5/-. The company had previously intimated the allotment details on July 20, 2026, confirming that the issuance was completed in accordance with the approved scheme.

Transaction Details

The following table outlines the key parameters of the share issuance and listing event:

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Ltd, signed the communication confirming receipt of the approvals from both exchanges on July 27, 2026.

What This Means for Shareholders

For former shareholders of J. B. Chemicals & Pharmaceuticals Limited, the commencement of trading on July 28, 2026, allows for the liquidation or holding of their converted equity stake in Torrent Pharmaceuticals Ltd. The seamless transition from allotment to listing indicates that all regulatory and exchange requirements for the amalgamation have been satisfied. Investors should monitor market movements during the initial trading sessions to assess price discovery for the newly listed shares.